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Abstract 
Rapid improvements in the detection and tracking of early-stage tumor progression 
aim to guide decisions regarding cancer treatments as well as predict metastatic 
recurrence in patients following surgery. Mathematical models may have the potential 
to further assist in estimating metastatic risk, particularly when paired with in vivo 
tumor data that faithfully represent all stages of disease progression. Herein we 
describe mathematical analysis that uses data from mouse models of spontaneous 
metastasis developing after surgical removal of orthotopically implanted primary 
tumors. Both presurgical (primary tumor) and postsurgical (metastatic) growth was 
quantified using bioluminescence and was then used to generate a mathematical 
formalism based on general laws of the disease (i.e. dissemination and growth). The 
model was able to fit and predict pre-/post-surgical data at the level of the individual 
as well as the population. Our approach also enabled retrospective analysis of clinical 
data describing the probability of metastatic relapse as a function of primary tumor 
size. In these data-based models, inter-individual variability was quantified by a key 
parameter of intrinsic metastatic potential. Critically, our analysis identified a highly 
nonlinear relationship between primary tumor size and postsurgical survival, 
suggesting possible threshold limits for the utility of tumor size as a predictor of 
metastatic recurrence. These findings represent a novel use of clinically relevant 
models to assess the impact of surgery on metastatic potential and may guide optimal 
timing of treatments in neoadjuvant (presurgical) and adjuvant (postsurgical) settings 
to maximize patient benefit.  
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Précis: A data-based mathematical model that assesses the impact of surgery on 
metastatic development may have clinical uses to individualize adjuvant therapies 
that can extend cancer remission.    
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Introduction 
Surgical removal of an early-stage localized tumor remains one of the most 
effective strategies in reducing the probability of systemic metastatic disease spread 
(1). Improved technologies of early cancer detection aim to classify primary tumor 
stage to identify whether potential treatment modalities – such as presurgical 
‘neoadjvuant’ or postsurgical ‘adjuvant’ – should be considered to complement 
surgery and reduce metastatic potential. However the relationship between primary 
tumor growth and eventual metastasis remains enigmatic (2). Metastatic seeding was 
initially thought to occur only during late stages of primary tumor growth and invasion 
(3), however, recent evidence suggests systemic dissemination is a much earlier 
event (4). Indeed even the direction of tumor spread, initially thought to occur uni-
directionally from primary to secondary sites, has been replaced by more complex 
and dynamic theories of interaction. These include models where primary and 
secondary lesions grow (and evolve) in parallel (2) and the possibility that cell seeding 
can be bi-directional, with metastasis potentially ‘re-seeding’ back to original primary 
location (5,6). 
To assist in understanding this complexity, mathematical modeling has been used 
to determine the relationship between primary (localized) and secondary (metastatic) 
tumor dissemination and growth. Early studies used statistical analyses only (7,8), 
while later work included experimentally-derived data to validate models using 
biological information that aimed to more faithfully represent the metastatic process 
(9). In 2000, Iwata and colleagues used imaging data from one patient with metastatic 
hepatocellular carcinoma to introduce a more formalistic and biologically-based 
approach that relied on the description of the temporal dynamics of a population of 
metastatic colonies, with equations written at the organ or organism scale (10). In 
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parallel, several studies have sought to include additional variables when modeling 
tumor growth, such as angiogenesis (11), stem cell behavior (12), tumor-immune 
interactions (13) and microenvironment influences (14), among numerous others. To 
date, the majority of mathematical studies in cancer modeling have focused on 
primary tumor and relatively few have investigated the metastatic development (15-
22). 
This dearth in metastatic data stems largely from the complexity of studying 
metastasis itself. Metastasis starts with localized primary tumor growth which then 
invades and intravasates into the bloodstream which, in turn, spreads systemically 
until extravating into tissue at a distant (hospitable) site (23,24). While clinical 
(retrospective) data has value (2,7,20,25,26), mouse tumor models have typically 
aimed to mimic (and distinguish between) several stages of the metastatic process. In 
certain mouse models, metastasis can derive from a tumor that is implanted 
ectopically or orthotopically into a primary or metastatic site (‘ectopic‘, ‘orthotopic’ or 
‘ortho-metastatic’ models, respectively (27)) and can involve various immune states 
(i.e., human xenograft or mouse isograft). Although more rarely performed, models 
can also include surgical resection of the primary tumor which allows for progression 
of clinically relevant spontaneous metastatic disease. These can include surgery 
following ectopic implantation (i.e., ‘ecto-surgical’, such as tumors grown in the ear or 
limb that are later amputated), or orthotopic implantation and resection (i.e., ‘ortho-
surgical’), which more faithfully represent patient disease. To date, no studies have 
utilized data from ortho-surgical metastasis models for mathematical analysis. 
Herein we describe a mathematical approach developed using data derived from 
two ortho-surgical metastasis models representing competent and incompetent 
immune systems with luciferase-tagged human breast (LM2-4LUC+) and mouse kidney 
(RENCALUC+) cell lines. We first defined a mathematical formalism from basic laws of 
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the disease (dissemination and growth). Then we confronted the mathematical 
outputs to longitudinal measurements of primary tumor size, metastatic burden and 
survival using a population approach (nonlinear mixed-effects) for statistical 
estimation of the parameters. Minimally parameterized models of each experimental 
system were generated and used to fit and predict pre-/post-surgical data at the 
individual and population levels. Next we used clinical datasets to assess metastatic 
relapse probability from primary tumor size and show that, in both cases (preclinical 
and clinical), one specific parameter (�) allowed quantification of inter-
animal/individual variability in metastatic propensity. Critically, our models confirm a 
strong dependence between presurgical primary tumor size and postsurgical 
metastatic growth and survival. However, quantitative analysis revealed a highly 
nonlinear pattern in this dependency and identified a range of tumor sizes (either 
large or small) where variation of tumor size did not significantly impact on survival. 
These represent potential threshold limits for the utility of primary size as a predictor 
of metastatic disease (i.e., if small, then surgical cure; if large, then surgical 
redundancy). These findings represent the first time clinically relevant surgical models 
have been integrated with data-based mathematical models to inform the quantitative 
impact of presurgical primary tumor size on subsequent metastatic disease. 
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Quick guide to equations and assumptions 
The metastatic modeling approach we employed follows the formalism initiated by 
Iwata et al. (10), which was further developed/expanded in recent works in two key 
ways: 1) effect of systemic therapies (28,29), and 2) use in a (non-surgical) in vivo 
human xenograft model involving orthotopic primary tumors (PTs) and metastasis 
(21). Metastatic development is reduced to two main components:  
1) Growth: includes presurgical primary (�!) and secondary (�) tumor growth rates 
2) Dissemination: includes metastatic dissemination rate (�).  
A schematic description of the model is depicted in Figure 1. More complex 
considerations on the biology (1,30) and modeling (31) of the metastatic process have 
been considered elsewhere. 
Growth dynamics 
The PT volume �! �  solves the following equations  
 
��!
��
= �!(�!)
�! � = 0 = �!
 (1)  
The initial condition for the PT, denoted by �!, was determined either by the number of 
injected cells (preclinical case) or the initial tumor size at inception (clinical case, 
�! = 1 cell). Metastases were assumed to start from one cell. For each case, the 
optimal structure resulting from our investigations was to assume the same structural 
law for the PT and the metastases, although with possibly different parameter values. 
Preclinical : Human breast (LM2-4LUC+) metastasis model 
Growth dynamics were defined by  
1) Gomp-Exp (32) growth model (see expression below) 
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2)  Growth parameters for PT and metastases treated identically (� = �!)  
In a previous study quantifying the descriptive power of several growth kinetics 
models using data from the same breast animal model (33), the Gompertz model 
accurately described primary tumor growth curves, in accordance with a large body of 
literature (see references in (33)). However, a limitation of this model is that the tumor 
doubling time could become arbitrarily small for small volumes, a feature that we 
considered biologically irrelevant for small volumes at metastatic initiation (of the 
order of the cell). A lower bound to this doubling time might be expressed by the in 
vitro doubling time of the cell line, which can be experimentally determined. 
Consequently, we adopted the Gomp-Exp model (32), defined by   
 �! � = � � = min ��, � − � ln
�
�!
�  (2)  
Under this model, growth is divided between two phases: an initial exponential 
phase, followed by a Gompertz growth phase. Parameter �  is the maximal 
proliferation rate, taken here to be equal to the value inferred from in vitro proliferation 
assays (see supplementary Figure 1A and Table 2). The second term in the min 
function is the Gompertz growth rate, defined by two parameters. Parameter � is the 
intrinsic relative (specific) growth rate at the size �! of one cell. Parameter � is the 
exponential decay rate of the relative (specific) growth rate.  
Preclinical : Mouse kidney (RENCALUC+) metastasis model 
Growth dynamics were defined by  
1) Exponential growth model. 
2) Growth parameters for PT and metastases treated differently.  
In mathematical terms, this is expressed by 
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 �! � = �!�, � � = �� (3)  
Clinical : Human metastatic breast data 
Growth dynamics were defined by 
1) Gompertz growth model 
2) Growth parameters for PT and metastases treated identically (�! = �) 
Metastatic dissemination 
The formation of new metastases was assumed to occur at a PT volume-
dependent rate �(�!) having the following parametric expression  
 � �! = ��! (4)  
where parameter � is an intrinsic parameter of metastatic aggressiveness. This critical 
coefficient is the daily probability for a given tumor cell to successfully establish a 
metastasis. Therefore it is the product of several probabilities: 1) the probability of 
having evolved the necessary genetic mutations to ensure the phenotypic abilities 
required at each step of the metastatic process, 2) the survival probability of all 
adverse events occurring in transit including survival in the blood or immune escape, 
among others, and 3) the probability to generate a functional colony at the distant site. 
Following reported observations (34), we assumed that all the metastases were 
growing at the same volume (�)-dependent rate �(�) and that they all started from the 
same volume corresponding to the volume of one cell. The population of metastases 
was then formalized by means of a time (t)-dependent volume distribution � �, �  
solving the following problem (10): 
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�!� �, � + �! � �, � � � = 0 � ∈ (0,+∞),   � ∈ (�!,+∞) 
� �! � �,�! = � �! � � ∈ (0,+∞)
� 0, � = 0 � ∈ (�!,+∞)
 
� � = � �, � �� = � �! � �� = � �! � ��
!
!
,
!
!
!∞
!!
 
� � = �� �, � ��
!∞
!!
= � �! � − � � � ��
!
!
 
(5)  
The first equation is a continuity equation expressing conservation of the number of 
metastases when they grow. The second equation is a Neumann boundary condition 
on the flux of entering metastases at size � = �!. The third equation describes the 
initial condition (no metastases at the initial time). From the solution of this problem 
two main macroscopic quantities can be derived, the metastatic burden �(�) and the 
number of metastases �(�). In the convolution formula for �(�) (35), � �  represents 
a solution to the Cauchy problem (1) with � instead of �! and �! as initial condition. 
This formula allows fast simulation of the model using the fast Fourier transform 
algorithm (35), which was essential for estimation of the parameters that required a 
very large number of model evaluations. 
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Materials and methods 
Preclinical Methodology 
Cell lines 
The human LM2-4LUC+ cells are a luciferase-expressing metastatic variant of the 
MDA-MB-231 breast cancer-cell line derived after multiple rounds of in vivo lung 
metastasis selection in mice, as previously described (see (36) (37)). Mouse kidney 
RENCALUC+ cells expressing luciferase were a kind gift from R.Pili, Roswell Park 
Cancer Institute and described previously (38). LM2-4LUC+ and RENCALUC+ were 
maintained in Dulbecco’s modified Eagle’s medium (Corning, Cat. #MT10-013-CV) 
and in RPMI (Roswell Park Memorial Institute) medium (Corning, Cat. #MT15-041-
CV), respectively, with 5% heat-inactivated fetal bovine serum (Corning, Cat. #MT35-
010-CV). Cells were authenticated by STR profile comparison to ATCC parental cell 
database (for LM2-4LUC+) or confirmation of species origin (for RENCALUC+) (DDC 
Medical, USA). All cells were incubated at 37°C and 5% CO2 in a humidified 
incubator. 
Cell Proliferation assay 
LM2-4LUC+ cells were plated in 35mm plates (5x105 cells per plate) and were 
manually counted using trypan blue staining every 24 hours for 72 hours total (cellgro, 
Cat. #25-900-CI). 
Photon-to-cell ratio 
LM2-4LUC+ cells were trypsinized and counted. 5x106 cells were serial diluted 2 fold 
down to 9.77x103 cells and processed with Bright-Glo Luciferase Assay System 
(Promega, Cat. #E2610) following manufacture’s protocol. 
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Ortho-surgical models of metastasis 
Animal tumor model studies were performed in strict accordance with the 
recommendations in the Guide for Care and Use of Laboratory Animals of the 
National Institutes of Health and according to guidelines of the institutional Animal 
Care and Use Committee (IACUC) at Roswell Park Cancer Institute (Protocol: 1227M, 
to JMLE). 
The optimization and use of animal models of breast and kidney metastasis 
orthotopic primary tumor implantation and surgical resection have been extensively 
detailed elsewhere (39). Briefly, LM2-4LUC+ cells (2x106 cells in 50µL) and RENCALUC+ 
(4x104 cells in 5µL) were implanted, respectively, into the right inguinal mammary fat 
pad (right flank) or kidney (subcapsular space) of 6-8 week old female CB-17 SCID or 
Balb/c mice(39). Primary breast tumor size was assessed regularly with Vernier 
calipers using the formula width2(length×0.5) and in both tumor models animals were 
monitored bi-weekly for bioluminescence to quantify tumor growth (40).  See 
Supplementary preclinical methodology section for more details.  
Mathematical Methodology: Fit procedures 
Preclinical data: primary tumor and metastatic burden dynamics 
Three fit procedures were investigated: 1) fitting the population average time 
series, 2) individual fits of each mouse’s primary tumor (PT) and metastatic burden 
(MB) kinetics and 3) a mixed-effect population approach. Due to the high variability in 
the data, the first approach was not considered relevant. The second approach 
showed that the model was able to describe individual dynamics but, due to the 
relative scarcity of the data in a given animal, led to very poor identifiability of the 
coefficients, in particular the metastatic dissemination parameter � . The third 
approach was considered the most appropriate to our case. Indeed, nonlinear mixed-
effect modeling (41) is a statistical technique specifically tailored for sparse serial 
measurements in a population. It assumes that inter-animal variability can be 
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described by a parametric distribution on the model’s parameters (here assumed to 
be lognormal, consistently with other works (20,42)). Multiple strategies were tested in 
order to find the appropriate formalism to fit the data. These included fitting PT and 
MB separately or together. The strategy fitting PT and MB was ultimately selected 
because it resulted in more accurate fits and allowed for possible correlations 
between the primary and secondary tumors growth parameters in a same animal. 
One of the model parameters for Gomp-Exp growth was the in vitro proliferation 
rate, which was determined by an exponential fit to an in vitro proliferation assay. 
Maximization of the likelihood function under nonlinear mixed-effect formalism was 
solved using the function nlmefitsa implemented in Matlab (43), which is based on the 
stochastic approximation of expectation maximization (SAEM) algorithm. Specific 
assumptions were: log-transformation of the parameters (i.e. log-normal population 
distribution), proportional error model and full covariance matrix. For individual fits, 
weighted least squares minimization corresponding to individual likelihood 
maximization was performed using the function fminsearch of Matlab (Nelder-Mead 
algorithm), following previously reported methods (33). 
Clinical data: Calculation of metastatic relapse probability 
Our methodology for fitting the clinical data followed the same format as (44), 
although here the model was simplified (only parameter � was allowed to vary among 
individuals) and PT size at diagnosis was considered to be uniformly distributed within 
each size range. Parameters for the growth of the primary and secondary tumors 
were fixed (not subject to optimization) and corresponded to a maximal volume of 
10
!" cells (≃ 1 kg) and a doubling time of 7.5 months at 1 g, consistently with clinical 
values reported in the literature (8,25).  
The data reported in (26) consisted of metastatic relapse probabilities during the 
next 20 years post-surgery, for patients stratified by PT size (see Table 1). Diameter 
data from PT sizes at diagnosis were converted into volumes under the assumption of 
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a spherical shape and then converted to number of cells using the conversion rule 1 
mm3  ≃ 106  cells (45). Parameter �  was assumed log-normally distributed in the 
population, with mean �! and standard deviation �!. 
The probability of having a metastatic relapse in the next 20 years for a primary 
tumor diagnosed with a given size was assumed to be equal to the probability of 
already having one distant tumor at the time of diagnosis. For a given volume range 
of PT sizes at diagnosis �! ,�!!! , � ∈ {1,⋯ ,7}, we considered the diagnosis volume 
�!
! as a random variable uniformly distributed in �! ,�!!! . Then, we computed the 
corresponding age of the tumor at diagnosis (i.e. the time elapsed from the first 
cancer cell) from the assumption of Gompertzian growth with the parameter values 
previously mentioned. This quantity was denoted �!(�!
!). Under our formalism, the 
probability of having a disseminated metastasis at time �!(�!
!) then writes  
 ℙ Met!; �! , �! = ℙ � �! � �� > 1
!! !!
!
!
 (6)  
where Met! stands for the event of having one metastasis at diagnosis when the PT 
volume is in �! ,�!!! . For any volume range and value of �! and �!, this formalism 
allowed us to compute a probability to be compared to the respective empirical 
proportion of relapsing patients reported in (26), by simulating the two random 
variables involved (�!
!  and � ). We then determined the best-fit parameters by 
minimizing the sum of squared errors to the data, using the function fminsearch from 
Matlab. 
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Results 
Quantitative and differential modeling of metastasis in ortho-
surgical models 
To mimic clinical progression of spontaneous systemic metastatic disease, two 
models involving orthotopic tumor implantation and surgical resection (ortho-surgical) 
were employed. These included a xenograft breast model (LM2-4LUC+ cells implanted 
into the mammary fat pad) and an isograft kidney model (RENCALUC+ implanted into 
the subcapsular kidney space) (38) (see Methods). Presurgical primary tumor (PT) 
and postsurgical metastatic burden (MB) were tracked by bioluminescence (BL) 
emission, expressed in photons/second (p/s) (Figure 2A).  
In the breast model, simultaneous BL and gross tumor volume measurements 
(caliper) were performed. The former only quantifies living cells whereas the latter 
computes a total volume indifferently of its composition. Volume and BL emission 
were significantly correlated (supplementary Figure 1B), as observed by others (46). 
Determination of the signal corresponding to one cell was required in our modeling for 
the value assigned to �!. Based on linear regression between BL emission and tumor 
volume, we established that BL = 2.19·106 V + 7.89·107, where BL is the 
bioluminescence in p/s and V is the volume in mm3. This relationship, evaluated at V 
= 10 mm3 ≃ 107 cells gives 1 cell ≃ 10.08 p/s, which was approximated to 10 p/s.  
Using this value gave reasonable fits to the PT growth data (supplementary Figure 2).  
Validation and calibration of the mathematical model 
We assessed the ability of the models to describe and predict the experimental 
data of postsurgical MB dynamics. Several model designs were evaluated to define 
the optimal structure and methodology that would allow accurate and reliable data 
description. Specifically, for each in vivo experimental system, multiple structural 
expressions and parametric dependences between the growth rate of the PT and MB 
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were tested. We refer to supplementary Figures 3 and 4 for direct comparison of 
goodness-of-fit and identifiability under different modeling setups. Population and 
individual fits of the best models to the data are shown in Figures 2B-C (and 
supplementary Figure 5), and Figure 3, respectively. The parameter values inferred 
from the population fits are reported in Table 2. The mathematical models – combined 
with the population distribution of the parameters inferred from the nonlinear mixed-
effects statistical procedure – were able to give reasonable descriptions of the 
presurgical PT and postsurgical MB growth. Importantly, these combinations could 
quantify the dynamics of the process as well as the inter-animal variability. The latter 
was better characterized by the metastatic potential parameter � (large coefficients of 
variation in Table 2). The models could also fit individual dynamics of longitudinal data 
of pre-surgical PT and post-surgical MB (see Figure 3 for some representative 
examples of growth dynamics in particular mice and supplementary Figures 6 and 7 
for fits of all mice). 
In addition to their descriptive power, the models were able to predict growth 
dynamics in external data sets that were not employed for estimation of the 
parameters (Figure 2D-E). These results emphasize the ability of our general 
modeling structure to capture MB growth dynamics. Additionally, the modeled post-
surgical MB could also be related to empirical survival by means of a lethal burden 
threshold, which was estimated to be 4×10! p/s (supplementary Figure 8).  
Qualitative and quantitative differences across ortho-surgical models 
Xenograft Model: Breast metastasis 
Using the same growth model (Gomp-Exp) and parameters for both presurgical PT 
and postsurgical MB, we were able to adequately fit the data, while ensuring 
reasonable standard errors on the parameters estimates (Table 2). Although more 
complex structures (e.g. models with one parameter differing between primary and 
secondary growth) provided marginally better fits, robustness in estimating �  was 
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impaired (supplementary Figure 3). Quantitative inference of �  revealed small 
metastatic potential (Table 2), which translated into late development of metastases 
following xenograft and growth of the MB mostly dominated by proliferation (Figures 
2B, 3A-C). 
Isograft Model: Kidney metastasis 
In contrast, the kidney model MB growth curves exhibited a different behavior, with 
a marked change of regimen at the time of surgery. In the context of the model, this 
means that most of the presurgical MB increase was driven by the dissemination 
process, and not by proliferation of the metastases themselves. This was reflected by 
a very large value of �  (Table 2), with nine orders of magnitude of difference 
compared to the breast model. This feature was not directly visible, nor quantifiable, 
by direct examination of the data, and reflects the large metastatic aggressiveness of 
isograft spontaneous metastasis animal models, since overpassing the immune 
surveillance is a major challenge in the metastatic process (4). When the PT was 
removed, dissemination stopped and only proliferation remained for further growth of 
the MB, which happened at a slower rate than at the primary site (Figures 2C and 3D-
F). In some cases, growth of the MB remained constant or even decreased after 
surgery (see supplementary Figure 7). This result reflects the fact that the competent 
immune status of the mice might have an important impact on the establishment of 
durable, fast-growing metastatic colonies at the secondary sites (47).  
Together, our data-based quantitative modeling analysis of presurgical PT and 
postsurgical MB growth kinetics demonstrated the descriptive power of the models, 
unraveled distinct growth patterns between the two animal models and emphasized 
the critical role of the parameter � for quantification of the inter-animal variability. 
Clinical data of metastatic relapse probability 
Clinical data reported in the literature generally do not provide detailed information 
about the untreated growth of the metastatic burden, either because the residual 
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disease is invisible, or because the patients benefit from adjuvant therapy after 
resection of their PT. Nevertheless, before the generalization of adjuvant therapy for 
breast cancer, Koscielny et al. (26) reported data from a cohort of 2648 patients 
followed for 20 years after surgery of the PT, without additional treatment. Their data 
(reproduced in Table 1) demonstrated that, despite a clear association between PT 
size at diagnosis and the probability of metastatic relapse, not all the patients having 
a given PT size were relapsing. For instance, only 42% of patients with a PT diameter 
at diagnosis between 2.5 and 3.5 centimeters developed metastasis. Based on this 
observation, we used our model to describe inter-individual variability by means of a 
limited number of parameters. We considered that the probability of developing a 
metastasis in the next 20 years was equal to the probability of already having one at 
the time of diagnosis (see Methods). Using a lognormal population distribution of 
parameter � we were able to obtain a significant fit to the data of metastatic relapse 
for all size ranges (Table 1, p = 0.023). Interestingly, the median value of � resulting 
from these human data was close to the value from the preclinical breast data, in 
comparison to the kidney model. 
These results demonstrated that, within our semi-mechanistic modeling approach, 
parameter � was able to capture the inter-individual metastatic variability, not only in 
animal models, but also for patient data.  
Assessing the impact of surgery on metastasis and survival: a 
simulation study 
When diagnosis detects only a localized primary tumor, distant occult disease 
might already be present. In our model, the extent of this invisible metastatic burden 
depends on: 1) the PT size at diagnosis and 2) the patient’s metastatic potential �. 
For instance, if the PT size (or �) is small then the occult MB might be negligible and 
surgery would substantially benefit to the patient in terms of metastatic reduction, by 
stopping further spread of new foci. Conversely, if the PT size (or �) is large, then the 
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occult MB might already be consequent and removing the PT might only have a 
marginal impact.  
Virtual simulation of two breast cancer patients 
We simulated the quantitative impact of PT surgery in two virtual breast cancer 
patients having a PT diagnosed at 4.32 cm and two values of � (median and 90th 
percentile within a population distributed according to our previous estimate). Results 
are reported in Figure 4 and supplementary movies 1 and 2. A discrete and stochastic 
version of the metastatic dissemination was employed here for the simulations (see 
supplementary methods for details). Interestingly, our simulation revealed that at the 
time of diagnosis, no metastasis was detectable (i.e. below the imaging detection 
limit, taken here to 10! cells), in both cases (Figure 4A-B). In clinical terms, this 
means that both patients would have been diagnosed with a localized disease. 
However, the two size distributions were very different, with a much larger residual 
burden in the “large �” case, illustrative of the increased metastatic potential.  
For the “median � ” case, our model predicted the presence of two small 
metastases, with respective sizes 6 and 278 cells. Not surprisingly, when no surgery 
was simulated, this number continued to increase, reaching 160 secondary lesions 
after 15 years (Figure 4C). However, most of the metastatic burden (126 tumors, i.e. 
78.8% of the total burden) was composed of lesions smaller than 109 cells (≃1g). 
Panels E and G of Figure 4 demonstrate that a substantial relative benefit (larger than 
10%) in MB reduction was eventually obtained, but only after 7.8 years. Nevertheless, 
at the end of the simulation (15 years after surgery), the predicted two occult 
metastases at diagnosis had reached substantial sizes (1.41×10!!  and 1.89×10!! 
cells). Therefore, for this patient with median metastatic potential, the model indicates 
an important benefit in using adjuvant therapy. 
For a patient with higher metastatic potential (at the level of the 90th percentile, 
see Figure 4 panels B, D, F and H, and supplementary movie 2), even with a PT 
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diagnosed at the same size, the predicted metastatic burden at diagnosis was 
considerably more important, with 76 lesions and the largest comprising 6.23×10! 
cells. This consequent occult burden translated into poor outcome and the metastatic 
mass would have reached a lethal burden of 10!" cells 9.3 years after the initial 
diagnosis if no therapy would have been administrated. 
These results illustrate the potential of the model as a diagnosis and prognosis 
numerical tool for assessment of the occult metastatic burden and post-surgery 
growth. In this, it could help to determine the extent of adjuvant therapy necessary to 
achieve a long-term control of the disease. 
Impact of tumor size on postsurgical survival 
To further examine the relationship between the PT size at surgery and survival, 
we performed simulations for 1) an individual with fixed value of � (the population 
median, see Figure 5A) or 2) an entire population (simulated survival curves in Figure 
5B), for three PT sizes. Numerical survival was defined by the time to reach a lethal 
burden of 1 kg (≃ 10!" cells) (2) from the time of cancer inception. Interestingly, we 
observed a highly nonlinear relationship between the PT size and the survival, which 
suggested three size ranges delimited by two thresholds (Figure 5A). The lower 
threshold — termed ‘recurrence’ threshold (4 cm in Figure 5A) — was defined as the 
maximal limit whereupon no metastasis was present at surgery (number of 
metastases lower than 1). The upper size threshold — termed ‘benefit’ threshold 
(5.2 cm in Figure 5A) — was defined as the size above which surgery had a negligible 
(< 10%) impact on survival time. Above and below these ‘recurrence’ and ‘benefit’ 
thresholds, PT size had no important correlative value. Conversely, within the PT size 
range delimited by these two bounds, the relationship between presurgical PT and 
postsurgical MB/survival was highly correlative, with a large derivative and a sharp 
transition between the two extremes. The same qualitative PT size/survival 
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relationship was obtained for any value of � sampled within the population distribution 
(see supplementary Figure 9). 
In Figure 5C, we present quantitative estimates of the recurrence and benefit 
thresholds for various percentiles of �  within the population distribution (see also 
supplementary Figure 9). Our simulations predicted that for the first half of the 
population, surgery was almost always leading to negligible metastatic recurrence 
risk, with large values of the recurrence threshold (larger than the usual detection 
levels). On the other hand, the patients with large metastatic potential were predicted 
not to substantially benefit from the surgery, as far as reduction of future MB was 
concerned. For instance, a patient with � at the level of the 90th percentile and a PT 
diagnosed at 4 cm would have an increase in absolute survival time of only 1.9% 
following surgery (Figure 5C).  
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Discussion 
Using a formalism based on simple laws of metastatic development (including 
dissemination and proliferation), we derived mathematical models able to connect 
presurgical PT growth to postsurgical development of the MB in two ortho-surgical 
animal models (with two immune states) as well as one clinical data set. These 
quantitative models allowed identification of different metastatic growth patterns and 
characterization of the metastatic potential (and associated inter-animal/individual 
variability) as a critical parameter, �. Our results also revealed a nonlinear quantitative 
relationship between the PT size at diagnosis and post-surgical survival improvement. 
Previous studies have utilized experimental data derived from mouse metastasis 
models to inform mathematical analysis. For instance, Hartung and colleagues used 
human MDA-MB-231 breast cancer cells implanted orthotopically in mice in order to 
validate a mathematical model for longitudinal data of metastatic burden growth (21). 
This animal model was non-surgical and utilized severe immunocompromised Nod 
SCID � mice to improve the low metastatic potential observed in the MDA-MB-231, a 
phenomena recently reported elsewhere (47). In our studies, we utilized a variant of 
the MDA-MB-231 previously selected for increased metastatic potential by repeated 
orthotopic implantation and metastatic resection in SCID mice (36). Since the 
selection of cells and immune state could influence analysis, we also included an 
immunocompetent mouse kidney model to confirm (and compare) findings. While 
these and other modifications to the metastatic systems could significantly influence 
mathematical modeling (i.e., different mouse strain and cell line, different 
bioluminescence technique, etc…), the impact of surgery appears to be the most 
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significant factor. In this regard, several technical discrepancies likely impair a 
relevant comparison between surgical and non-surgical models presented by 
Hartung, et al. (21) and the current study. For instance, in surgical models we found it 
unnecessary to assume different growth between the primary and secondary lesions 
in surgical models. Additionally, we considered a less complex dissemination rate 
(expression � �! = ��!
!
 and � =
!
!
 was used in (21)). Notably, we could fit our data 
equally well with various values of � and thus concluded that it cannot be identified 
from combined PT growth and MB dynamics data alone (supplementary Figure 10). 
Future studies would require more data, especially on the number and size 
distribution of the secondary lesions, to precisely determine the shape of the 
dissemination coefficient. When using the dissemination and growth terms from (21) 
and fitting the resulting model to our surgical data, we found a much larger metastatic 
potential �  and a significantly faster metastatic growth kinetics parameter than 
computed  in the non-surgical model (21) (see supplementary text). While the former 
probably illustrates higher metastatic propensity due to a more permissive immune 
state, the latter possibly suggests post-surgery metastatic acceleration (48-50).  
In this regard, this raises another critical consideration of the impact of surgery on 
metastatic potential in mathematical modeling. Preclinical and clinical works have 
suggested that removal of the PT might provoke acceleration of metastatic growth 
(50,52). There are various biological rationales that could explain this, including 
inhibition of secondary growth by the presence of a primary neoplasm as a result of 
nutrient availability, concomitant immunity, or even systemic inhibition of angiogenesis 
(53). Such a theory could conceivably be assessed within the context of our model by 
defining different pre- and post-surgical metastatic growth rates �(�) and comparing 
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goodness of fit. However, this would add at least one degree of freedom (thus 
deteriorating the reliability of the estimation) and invalidate the convolution formula 
used for computation of the metastatic burden in a model with non-autonomous 
�(�, �)  (instead of �(�) ), and therefore was not considered here. Importantly, 
theoretical integration of higher order phenomena for the biological dynamics of 
metastatic development has been considered elsewhere (14,16,18,54) and recent 
findings in the organism-scale dynamics of metastases (such as the self-seeding 
phenomenon (5,6) or the influence of the (pre-) metastatic niche (55)) could be 
embedded within the general formalism developed in our model. This could lead to 
complex models, however, and given the amount of information contained in our 
present data, reliable identification of such dynamics was not realistic. Instead, we 
only considered metastatic dynamics as reduced to its most essential features: 
dissemination and proliferation. Future studies should examine the potential of 
metastases to metastasize, as has been extensively debated in the past (56-58), 
particularly with the recent demonstration that some metastases are able to re-seed 
the primary tumor (5,6). Although not included in this study, preliminary tests using 
our model suggest negligible differences in the simulations and no impact on our 
results, however a more extensive analysis is required. 
Our modeling philosophy elaborates on Fisher’s theory (59) of cancer as a 
systemic disease and relates also to the parallel progression model (2). The 
dissemination rate �, characterized by parameter �, quantifies the metastatic potential 
and allows for a continuum of possibilities between early and late dissemination. Our 
results seem to parallel clinical evidence of the impact (and importance) of early 
surgery – particularly in the case of breast cancer. For example, in a retrospective 
study of 2838 breast cancer patients, the post-surgical residual recurrence-free 
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survival rate at 5 years for Stage I disease was 7% (60). Consistently, our quantitative 
analysis demonstrates that in this case, for most patients, metastases that could have 
been shed before diagnosis would not develop into overt clinical disease during the 
remaining life history of the patient. For Stage IV breast cancer (that would 
correspond, in our formalism, to a large value of � ), our analysis predicts only 
negligible benefit of the surgery (if only considering reduction of metastatic shedding), 
in accordance with preliminary results of a recent clinical trial (61). In order to use our 
model as a practical diagnosis and prognosis tool that could help to refine and 
individualize adjuvant therapy, the critical next step is to find a way to estimate the 
parameter �, in a patient-specific manner. One of the main challenges will be to do so 
using data derived from the primary tumor only, since metastases are often 
undetectable at the time of diagnosis. While the value of � might very likely depend on 
the combination of several phenomena (including some genetic alterations or the 
immune status of the patient which could be linked to different biomarkers (62)), 
recent successes of genetic signatures as prognosis factors for metastasis might 
allow for patient-specific estimation of � (63). 
Any mathematical modeling attempt is limited by the intrinsic measurement error of 
the experimental technique. For monitoring the dynamics of total metastatic burden, 
bioluminescence imaging represents one of the best methods so far (51). However, 
measurement variability is hard to assess due to inherent issues, such as the long 
half-life of luciferin that prevents immediate replication of the measurements. 
Comparison of bioluminescence with caliper measurements showed large variance 
(supplementary Figure 1B), which increased with tumor size. This justified our 
assumption of a proportional measurement error model. Standard deviation of the 
relative error could in turn be estimated from the fit procedure and yielded a value of 
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0.72. This high degree of uncertainty should be taken into account as an inevitable 
limitation for quantitative modeling studies of bioluminescence data. We therefore put 
a strong emphasis on using a minimal number of parameters and assessed the 
robustness of our results on various assumptions, such as the shape of � and the 
value of �! (supplementary Figures 10 and 11).  
Together, our mathematical methodology provides a quantitative in silico 
framework that could be of valuable help for preclinical and clinical aims. Indeed, 
validation of our modeling methodology allows us to address in future works the 
differential effects of systemic therapies on primary tumor growth and metastases 
(39,40). Clinically, our methodology could be used to refine/optimize therapeutic 
strategies for patients diagnosed with a localized cancer and inform on the timing of 
surgery, extent of occult metastatic disease and probability of recurrence. In turn, this 
may impact decisions on duration and intensity of presurgical neoadjuvant or 
postsurgical adjuvant treatments (64).  
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Table 1: Descriptive power of the mathematical model: clinical data of metastatic relapse probability
Diameter (cm) No. patients Prop. of relapse (Data) Prop. of relapse
(Model)
1 ≤ D ≤ 2.5 317 27.1 25.5
2.5 < D ≤ 3.5 496 42.0 42.4
3.5 < D ≤ 4.5 544 56.7 56.3
4.5 < D ≤ 5.5 422 66.5 65.9
5.5 < D ≤ 6.5 329 72.8 74.3
6.5 < D ≤ 7.5 192 83.8 80.8
7.5 < D ≤ 8.5 136 81.3 85.7
Fit of the model was significant for Pearson’s χ2 test for goodness-of-fit (p = 0.023).
Table 2: Parameters inferred from the models
Data Growth model Location Par. Unit Estimate (CV) 95 % CI
In vitro (Breast) Exp. λ day−1 0.837 (-) (0.795 - 0.879)
Preclinical Breast Gomp-Exp.
PT
Vi cell 1.00 × 10
6 (-) -
α day−1 1.9 (5.73) (1.84 - 1.96)
β day−1 0.0893 (21.3) (0.0791 - 0.101)
Met
V0 p/s 10 (-) -
µ cell−1 · day−1 4.43 × 10−11 (176) (2.70 × 10−11 - 7.27 × 10−11)
Preclinical Kidney Exp.
PT
Vi p/s 1.63 × 10
5 (45.5) (9.40 × 104 - 2.83 × 105)
αp day
−1 0.21 (60.3) (0.151 - 0.292)
Met
V0 p/s 10 (-) -
α day−1 0.0307 (201) (0.0133 - 0.0707)
µ cell−1 · day−1 0.0415 (397) (0.0181 - 0.0948)
Clinical Breast Gomp.
PT
Vi cell 1 (-)
α day−1 0.013 (-)
β day−1 0.000471 (-)
Met
V0 cell 1 (-)
µ cell−1 · day−1 7.00 × 10−12 (1.04 × 104)
Parameters corresponding to the preclinical data were obtained using nonlinear mixed-effects modeling. Inter-animal variability of each parameter is
captured by its respective coefficient of variation (CV). Parameter values for the clinical data are those that produced the fit to the clinical data of metastatic
relapse probability from (26), reported in Table 1. For these data, only parameter µ was allowed to vary between the individuals in this setting and
consequently it is the only parameter having a coefficient of variation (CV).
CV = Coefficient of Variation in percent = std
est
× 100, with std the standard deviation of the lognormal distribution of the parameter and est the population
estimate.
CI = Confidence Interval on the population estimate inferred from the standard errors on the fit.
Supplementary Figures
Supplementary Figure 1. In vitro fit and direct statistical analysis of the xenograft breast data
(LM2-4luc+)
Supplementary Figure 2. Population fit of the tumor growth data that were measured by BL, under
the Gomp-Exp model and initial volume V0 fixed by the conversion rule inferred from the correlation
between volume and BL (V0 = 10 p/s)
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Supplementary Figure 7. Individual fits of primary tumor and metastatic burden kinetics. Kidney
animal model
Supplementary Figure 8. Link between experimental and model survival
Supplementary Figure 9: Surgery benefit on survival and metastatic burden reduction as a function
of resection size, for varying values of metastatic potential (parameter µ)
Supplementary Figure 10. Population fits of the ortho-surgical metastasis animal models for a
dissemination coefficient d(Vp) = µV
γ
p and various values of γ
Supplementary Figure 11. Population fits of the ortho-surgical metastasis animal models for vari-
ous values of the signal-to-cell ratio V0
Supplementary Movie 1: Simulation of the cancer history from the first cancer cell for a virtual
patient with median µ
Supplementary Movie 2: Simulation of the cancer history from the first cancer cell for a virtual
patient with large µ, at the 90th percentile.
Supplementary Figure 1. In vitro fit and direct statistical analysis of the xenograft
breast data (LM2-4luc+)
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A. In vitro proliferation kinetics and exponential fit of the LM2-4luc+ cell line. Three replicates
B. Correlation between bioluminescence emission and caliper-measured volume of the primary tumor
C. Correlation between PT volume at resection and final metastatic burden
PT = Primary Tumor
Supplementary Figure 2. Population fit of the tumor growth data that were mea-
sured by BL, under the Gomp-Exp model and initial volume V0 fixed by the con-
version rule inferred from the correlation between volume and BL (V0 = 10 p/s)
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Fit was performed using nonlinear mixed effects modeling (function nlmefitsa of Matlab). Plain line is the median
output from the model under the inferred population distribution and dashed lines are 10% and 90 % percentiles.
The good quality of the fit gives an a posteriori rationale for the relevance of our value of V0.
Supplementary Figure 3. Population fits of the breast xenograft data under differ-
ent growth theories
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Model Par. Unit Median value (CV) NSE (%)
Diff growth alpha fixed
αP day
−1 0.605 (9.83) 3.57
βP day
−1 0.0786 (12.2) 4.86
µ cell−1 · day−1 3.01e-09 (820) 72.1
β day−1 0.0816 (15.7) 5.06
Same growth
α day−1 0.664 (16.3) 4.76
β day−1 0.0893 (21.3) 6.21
µ cell−1 · day−1 4.43e-11 (176) 26.5
Fits of the breast xenograft data under two models.
A: Same growth = same Gompertz growth parameters (α and β) for primary and secondary tumors.
B: Different growth alpha fixed = for each animal, same value of parameter α was imposed while value of β was
allowed to vary between the PT and the secondary tumors.
C: Parameters estimates under the two different models.
With similar visual accuracy of the population fits (also observable in individual fits of particular mice, data not
shown), the second model generated substantially higher uncertainty on the parameter estimation, especially pa-
rameter µ, with respective normalized standard errors (NSE) of 26.5% for the “same growth” model and 72.1% for
the “different growth with alpha fixed” model. Additionally, probably due to sharper estimation of the parameters,
predictive performances were improved with the “same growth” model (results not shown).
Supplementary Figure 4. Population fits of the kidney isograft data under different
growth theories
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Model Par. Unit Median value (CV) NSE (%)
Diff growth exp
Vi p/s 1.63e+05 (45.5) 29.9
αP day
−1 0.21 (60.3) 17.2
µ cell−1 · day−1 0.00415 (397) 48.4
α day−1 0.0307 (201) 48.9
Same growth exp
Vi p/s 8.05e+05 (779) 53.7
α day−1 0.0831 (325) 40.4
µ cell−1 · day−1 0.000892 (2.88e+03) 77.4
Fits of one of the datasets for the isograft kidney model (surgery at day 23) under two models for the growth of
secondary tumors in relationship to the PT. At the structural level, both growths were considered exponential.
A: Same growth rate between primary and secondary tumors.
B: Different growth rate between primary and secondary tumors.
C: Parameters estimates under the two different models.
We chose the second model to be best adapted because: 1) the population fit was more accurate, especially for
description of the inter-animal variability, 2) adding a parameter did not result in deterioration of the normalized
standard errors (NSE) of the parameters estimates and 3) the low descriptive power of the “same growth” model
was confirmed by a large inaccuracy in individual fits (results not shown)
Supplementary Figure 5. Second kidney data set used for fitting the data (resec-
tion time = 23 days)
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Supplementary Figure 6. Individual fits of primary tumor and metastatic burden
kinetics. Breast animal model
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Equivalent of Figure 3 with all the animals. Each animal was fitted separately.
Supplementary Figure 7. Individual fits of primary tumor and metastatic burden
kinetics. Kidney animal model
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Equivalent of Figure 3 with all the animals. Each animal was fitted separately.
Supplementary Figure 8. Link between experimental and model survival
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Predicted versus experimental survival. The model survival was defined as the time to reach a given lethal burden
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Supplementary Figure 9: Surgery benefit on survival and metastatic burden re-
duction as a function of resection size, for varying values of metastatic potential
(parameter µ)
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Supplementary Figure 10. Population fits of the ortho-surgical metastasis animal
models for a dissemination coefficient d(Vp) = µV
γ
p and various values of γ
γ = 0.1 γ = 0.5 γ = 1
LM2-4luc+
A
Time (days)
0 10 20 30 40 50 60 70
Pr
im
ar
y 
tu
m
or
 s
ize
 (c
ell
s)
104
106
108
1010
M
et
as
ta
tic
 b
ur
de
n 
(ce
lls
)
104
106
108
1010
Orthotopic
implantation
Surgery
(t=34)
Pre-surgical
PT
Post-surgical
MB
B
Time (days)
0 10 20 30 40 50 60 70
Pr
im
ar
y 
tu
m
or
 s
ize
 (c
ell
s)
104
106
108
1010
M
et
as
ta
tic
 b
ur
de
n 
(ce
lls
)
104
106
108
1010
Orthotopic
implantation
Surgery
(t=34)
Pre-surgical
PT
Post-surgical
MB
C
Time (days)
0 10 20 30 40 50 60 70
Pr
im
ar
y 
tu
m
or
 s
ize
 (c
ell
s)
104
106
108
1010
M
et
as
ta
tic
 b
ur
de
n 
(ce
lls
)
104
106
108
1010
Orthotopic
implantation
Surgery
(t=34)
Pre-surgical
PT
Post-surgical
MB
Rencaluc+
D
Time (days)
0 20 40 60 80
Pr
im
ar
y 
tu
m
or
 s
ize
 (c
ell
s)
104
106
108
1010
M
et
as
ta
tic
 b
ur
de
n 
(ce
lls
)
104
106
108
1010
Orthotopic
implantation
Surgery
(t=23)
Pre-surgical
PT
Post-surgical
MB
E
Time (days)
0 20 40 60 80
Pr
im
ar
y 
tu
m
or
 s
ize
 (c
ell
s)
104
106
108
1010
M
et
as
ta
tic
 b
ur
de
n 
(ce
lls
)
104
106
108
1010
Orthotopic
implantation
Surgery
(t=23)
Pre-surgical
PT
Post-surgical
MB
F
Time (days)
0 20 40 60 80
Pr
im
ar
y 
tu
m
or
 s
ize
 (c
ell
s)
104
106
108
1010
M
et
as
ta
tic
 b
ur
de
n 
(ce
lls
)
104
106
108
1010
Orthotopic
implantation
Surgery
(t=23)
Pre-surgical
PT
Post-surgical
MB
A - C: Xenograft breast model (LM2-4luc+)
D - E: Isograft kidney model (Rencaluc+). Only group with surgery at t = 23 days is shown.
Other intermediate values of γ between 0 and 1 produced similar, visually equivalent fits.
Supplementary Figure 11. Population fits of the ortho-surgical metastasis animal
models for various values of the signal-to-cell ratio V0
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V0 (p/s) 1.0 10.0 100.0
LM2-4luc+ 4.43× 10−10 4.16× 10−11 4.50× 10−12
Rencaluc+ 0.0298 0.0348 0.0375
The relationship between BL and volume was far from perfectly linear in supplementary Figure 1B. This suggests
that, for detectable volumes, the number of living tumor cells might not be proportional to the tumor volume, consis-
tently with general laws of tumor growth (37). Hence, considering the relatively poor reliability of the extrapolated
value of V0, simulations were performed to test the robustness of the results with respect to the value of V0, by
varying V0 over two orders of magnitude. Similar fits were obtained for the metastatic burden (MB) (supplementary
Figure 10), showing that, for our concern here (the MB), different values of V0 were virtually equivalent.
A - C: Xenograft breast model (LM2-4luc+)
D - E: Isograft kidney model (Rencaluc+). Only group with surgery at t = 23 days is shown.
Goodness-of-fit performances were the same for each value of V0. The data is shifted along the y-axis because the
conversion rule was used to convert the bioluminescence data into cell numbers. For the breast data, primary tumor
volumes were measured in mm3 using calipers and then converted into cell numbers using the conversion rule 1
mm3 ≃ 106 cells. Hence, the conversion did not depend on V0 and the data was not shifted when changing V0.
G: Population estimate of µ (in cell−1· day−1) for the different values of V0.
Supplementary Movie 1: Simulation of the cancer history from the first cancer cell
for a virtual patient with median µ
Primary tumor (PT) was assumed to be detected when reaching the size of 4.32 cm in diameter. Post-diagnosis PT
growth and development of metastases in the case of no surgical intervention are indicated as dashed line in the left
plot and white bars in the histogram on the right, respectively.
Supplementary Movie 2: Simulation of the cancer history from the first cancer cell
for a virtual patient with large µ, at the 90th percentile.
Primary tumor (PT) was assumed to be detected when reaching the size of 4.32 cm in diameter. Post-diagnosis PT
growth and development of metastases in the case of no surgical intervention are indicated as dashed line in the left
plot and white bars in the histogram on the right, respectively.
Supplementary text
Using the model from [Hartung et al., 2014] on the LM2-4luc+ data
In [Hartung et al., 2014], Hartung, Mollard et al. had developed a similar modeling analysis on data from
breast cancer xenografts, however with no consideration of primary tumor surgery and in severely immune-
incompetent mice. Thus, it could have been interesting to see whether the modeling analysis brings any
insights on the differences between the cases with and without surgery. Unfortunately, quantitative compar-
ison was hampered by the following points: different number of cells injected, different mice strain (severe
combined immuno-deficient in our case versus Nod-scid gamma in their case), different bioluminescence
quantification method (2D versus 3D) that resulted in a different cell-to-signal ratio and integration of peri-
toneal metastases for them versus only pulmonary metastases for us. Keeping all these flaws in mind, we
nevertheless applied their model to our ortho-surgical data set of breast xenografts. This consisted in the use
of a dissemination coefficient with the form d(Vp) = µV
2/3
p , different growth rates for the primary tumor and
the metastases, and a different parameterization of the Gompertz growth rate, written as: g(V ) = aV ln
(
b
V
)
.
We obtained a significantly larger value of a in our data of 4.91×10−2 day−1 ± 2.02×10−3 versus 7.9×10−3
day−1 ± 2.5×10−3 in [Hartung et al., 2014] (population estimate± standard error). This could suggest post-
surgery acceleration of metastases. On the other hand, the value of µ was also found significantly different,
with several order of magnitudes of difference. We computed µ = 7.24× 10−3± 8.5× 10−3 cell−2/3· day−1
versus µ = 6.31 × 10−1 ± 4.42 × 10−1 cell−2/3· day−1 in [Hartung et al., 2014]. Indeed, it was already
visible in the data without performing any quantitative analysis that they obtained a larger metastatic burden
for smaller primary tumor sizes.
 1 
Supplementary methods 
 
Preclinical methodology 
Ortho-surgical models of metastasis 
For ortho-surgical metastasis models, we followed detailed experimental criteria to control 
for variable disease progression and model standardization as previously described [Ebos et 
al., 2014]. For example, in breast (LM2-4LUC+) and kidney (RENCALUC+) models, tumor 
invasion noted during surgery such as growth into peritoneal space (breast) or presentation 
of a non-encapsulated kidney tumor led to mouse exclusion from study. Additionally,  if no 
tumor was present at any time before and after surgery (determined by bioluminescence or 
visible macroscopically), mice were excluded from study so as not to give potential false 
positive or negative bias to results (see [Ebos et al., 2014]). Note: all animals used in this 
study represent vehicle-treated controls from published [Ebos et al., 2014] and unpublished 
studies involving sunitinib malate. Therefore all animals in this study were treated with 
10ml/kg vehicle for 7-14 days prior to tumor resection. Vehicle contained 
carboxymethylcellulose sodium (USP, 0.5% w/v), NaCl (USP, 1.8% w/v), Tween-80 (NF, 
0.4% w/v), benzyl alcohol (NF, 0.9% w/v), and reverse osmosis deionized water (added to 
final volume) and adjusted to pH 6 (see [Ebos et al., 2008]). Importantly, no difference in 
metastatic disease progression patterns or survival has been observed between vehicle and 
untreated animals ([Ebos et al., 2014] and data not shown). 
 
Bioluminescent imaging 
Quantification of local and disseminated tumor burden by bioluminescent imaging has 
been previously described in detail (see [Ebos et al., 2014] and [Ebos et al., 2008]). Briefly, 
mice were injected intraperitoneally with substrate D-luciferin at 150 mg/kg in Dulbecco’s 
 2 
Phosphate Buffered Saline (Corning, Cat. #MT21-031-CV) and, after a 10 minute interval, 
anesthetized (4% isoflurane in oxygen for induction, 2% for maintenance) and placed onto 
the warmed stage inside the light-tight camera box (IVIS™ ; Xenogen, Alemeda, CA)  as 
previously described ([Ebos et al., 2009] and [Ebos et al., 2014]). Light emitted from 
bioluminescent cells after 1 minute was detected by the IVIS® camera system with images 
quantified for tumor burden using a log-scale color range set at 5×104 to 1×107 and 
measurement of total photon counts per second (p/s) using Living Image software (Xenogen) 
Mathematical methodology: Stochastic dynamics of metastasis formation
The formalism we employed to fit the model to the data was deterministic, because fast simulations were
required for the large number of computations of the model needed for fitting the data. However, when consid-
ering simulation of individual dynamics (Figure 4), stochastic dynamics were simulated. The stochasticity here
refers to intra-individual randomness in the metastatic dissemination. The stochastic version of the model was
the following. The formation of new metastatic foci was assumed to be a sequence of random events expo-
nentially distributed with rate d(Vp(t)). The number of metastases followed then a Poisson processN (t) with
intensity d(Vp(t)). The appearance time of the i-th metastasis was defined by
Ti = inf {t ≥ 0; N(t) ≥ i}
Adapting the methodology of [Iwata et al., 2000] to the case of randomly distributed dissemination times and
denoting ρ˜ the resulting random size distribution of metastases, ρ˜ was a sum of Dirac masses solving the
following problem


∂tρ˜(t, v) + ∂v(ρ˜(t, v)g(v)) = 0 t ∈]0,+∞[, v ∈]V0,+∞[
g(V0)ρ˜(t, V0) =
∑
+∞
i=1 δ (t = Ti) t ∈]0,+∞[
ρ˜(0, v) = 0 v ∈]V0,+∞[
(1)
Equivalently, denoting by Vi the volume of the i-th metastasis, we have


dVi
dt
= g(Vi(t))
Vi(Ti) = V0, Vi(t) = 0, for t ≤ Ti
From these considerations the stochastic total metastatic burden at time t, denoted byM(t) was defined by
the following expression
M(t) =
∫
+∞
V0
vρ˜(t, v)dv =
+∞∑
i=1
Vi(t)
The two approaches (deterministic and stochastic) are in fact closely and consistently linked. It can be shown
[Hartung and Christophe, 2014] that the quantities M(t) and N(t) defined in the body text (section “quick
guide to equations and assumptions”) are the respective expectations ofM(t) and N (t).
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